Complications of multiple myeloma

被引:50
作者
Blade, Joan [1 ]
Rosinol, Laura [1 ]
机构
[1] Hosp Clin Barcelona, Inst Hematol & Oncol, Postgrad Sch Hematol Farreras Valenti, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain
关键词
D O I
10.1016/j.hoc.2007.08.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multiple myeloma, also known as myeloma or plasma cell myeloma, is a progressive hematologic disease. Complications of multiple myeloma include renal insufficiency, hematologic complications (anemia, bone marrow failure, bleeding disorders), infections, bone complications (pathologic fractures, spinal cord compression, hyercalcemia), and neurologic complications (spinal cord and nerve root compression, intracranial plasmacytomas, leptomeningeal involvement, among others). This article reviews these various complications connected to multiple myeloma, examining their various causes and possible treatment.
引用
收藏
页码:1231 / +
页数:17
相关论文
共 73 条
  • [1] ALEXANIAN R, 1990, ARCH INTERN MED, V150, P1693
  • [2] [Anonymous], EUR J HAEMATOL, DOI DOI 10.1034/J.1600-0609.2000.90218.X
  • [3] Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors
    Badros, A
    Weikel, D
    Salama, A
    Goloubeva, O
    Schneider, A
    Rapoport, A
    Fenton, R
    Gahres, N
    Sausville, E
    Ord, R
    Meiller, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) : 945 - 952
  • [4] Results of autologous stem cell transplant in multiple myeloma patients with renal failure
    Badros, A
    Barlogie, B
    Siegel, E
    Roberts, J
    Langmaid, C
    Zangari, M
    Desikan, R
    Shaver, MJ
    Fassas, A
    McConnell, S
    Muwalla, F
    Barri, Y
    Anaissie, E
    Munshi, N
    Tricot, G
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (04) : 822 - 829
  • [5] Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors
    Bamias, A
    Kastritis, E
    Bamia, C
    Moulopoulos, LA
    Melakopoulos, L
    Bozas, G
    Koutsoukou, V
    Gika, D
    Anagnostopoulos, A
    Papadimitriou, C
    Terpos, E
    Dimopoulos, MA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8580 - 8587
  • [6] American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma
    Berenson, JR
    Hillner, BE
    Kyle, RA
    Anderson, K
    Lipton, A
    Yee, GC
    Biermann, JS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3719 - 3736
  • [7] Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
    Berenson, JR
    Lichtenstein, A
    Porter, L
    Dimopoulos, MA
    Bordoni, R
    George, S
    Lipton, A
    Keller, A
    Ballester, O
    Kovacs, MJ
    Blacklock, HA
    Bell, R
    Simeone, J
    Reitsma, DJ
    Heffernan, M
    Seaman, J
    Knight, RD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) : 488 - 493
  • [8] CHEMOTHERAPY OF PLASMA-CELL MYELOMA AND THE INCIDENCE OF ACUTE-LEUKEMIA
    BERGSAGEL, DE
    BAILEY, AJ
    LANGLEY, GR
    MACDONALD, RN
    WHITE, DF
    MILLER, AB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1979, 301 (14) : 743 - 748
  • [9] BERGSAGEL DE, 1982, CLIN HAEMATOL, V11, P221
  • [10] BERGUIN Y, 1992, BRIT J HAEMATOL, V82, P648